What is the clinical evidence from this study?

Study design: Case Report. Population: Malignant melanoma with cardiac involvement (n=1). Intervention: BRAF/MEK inhibitors (dabrafenib and trametinib). Primary outcome: Resolution of cardiac metastasis.

What does this research mean for the field?

BRAF/MEK inhibitor therapy can achieve complete echocardiographic resolution of cardiac metastases in patients with BRAF V600E-mutated malignant melanoma. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To describe the clinical management, molecular diagnostic strategy, and treatment response of metastatic melanoma with right atrial involvement.

August 31, 2026Oncology in Clinical PracticeOpen Access

Malignant melanoma with cardiac involvement: a case report and literature review

View Full Paper

Ask AI

Bookmark

Why the study?

Cardiac involvement is found in up to 64% of melanoma patients at autopsy, yet antemortem diagnosis remains rare because patients are frequently asymptomatic.

Population

42-year-old woman with malignant melanoma and right atrial metastasis

Design

Case report and literature review

Follow-up

Approximately 3.5 years after diagnosis of cardiac metastasis

Key result

BRAF/MEK inhibitor therapy with dabrafenib and trametinib achieved complete resolution of a right atrial melanoma metastasis on transthoracic echocardiography.

Authors

AGAleksander Gorzeń TŚTomasz Świtaj PRPaweł Rogala

Discussion

Member takes

Overview

May support BRAF/MEK inhibitors for select melanoma cardiac metastases; hypothesis-generating and requires prospective validation.

Key Points

To describe the clinical management, molecular diagnostic strategy, and treatment response of metastatic melanoma with right atrial involvement.
Evaluated a 42-year-old woman presenting with lumbar melanoma and right atrial metastasis.
Performed pyrosequencing on subcutaneous metastatic tissue to detect the BRAF V600E mutation after primary tumor DNA testing was nondiagnostic.
Administered sequential systemic immunotherapies and targeted BRAF/MEK inhibitors (dabrafenib and trametinib) guided by serial echocardiography and electrocardiography.
Targeted BRAF/MEK inhibitor therapy achieved complete resolution of the right atrial metastasis on transthoracic echocardiography before later disease recurrence.
Electrocardiography detected asymptomatic abnormalities including sinus tachycardia, low QRS voltage, and nonspecific ST-T wave changes.
Overall survival reached approximately 3.5 years following the diagnosis of cardiac metastasis.

Study Design

Type

Case Report (n=1)

Multicenter

Structured PICO

Population

A 42-year-old woman with malignant melanoma and right atrial metastasis who was treated with targeted therapy and survived for approximately 3.5 years after cardiac metastasis diagnosis.

Intervention

Multiple lines of systemic therapy, including pembrolizumab, ipilimumab, and BRAF/MEK inhibitors (dabrafenib and trametinib), with serial echocardiographic monitoring.

Outcome

Regression of right atrial metastasis on serial transthoracic echocardiographysurrogate

BRAF/MEK inhibitor therapy can achieve complete resolution of cardiac metastases from melanoma, highlighting the importance of molecular testing and multimodal imaging surveillance.

Limitations

Single case report
Recurrence of the cardiac lesion upon disease progression highlights the limitations of durable tumor control
Initial BRAF testing of archival tissue was nondiagnostic due to DNA degradation

Cite This Study

Gorzeń et al. (2026) conducted a case report in Malignant melanoma with cardiac involvement (n=1). BRAF/MEK inhibitors (dabrafenib and trametinib) was evaluated on Resolution of cardiac metastasis. BRAF/MEK inhibitor therapy with dabrafenib and trametinib achieved complete resolution of a right atrial melanoma metastasis on transthoracic echocardiography.

synapsesocial.com/papers/6a953aec6af7ed2fcaea0c63 https://doi.org/10.5603/ocp.112654

View Full Paper

Ask AI

Bookmark

August 31, 2026Oncology in Clinical PracticeOpen Access

Malignant melanoma with cardiac involvement: a case report and literature review

View Full Paper

Ask AI

Bookmark

Why the study?

Cardiac involvement is found in up to 64% of melanoma patients at autopsy, yet antemortem diagnosis remains rare because patients are frequently asymptomatic.

Population

42-year-old woman with malignant melanoma and right atrial metastasis

Design

Case report and literature review

Follow-up

Approximately 3.5 years after diagnosis of cardiac metastasis

Key result

BRAF/MEK inhibitor therapy with dabrafenib and trametinib achieved complete resolution of a right atrial melanoma metastasis on transthoracic echocardiography.

Authors

AGAleksander Gorzeń TŚTomasz Świtaj PRPaweł Rogala

Discussion

Member takes

Overview

May support BRAF/MEK inhibitors for select melanoma cardiac metastases; hypothesis-generating and requires prospective validation.

Key Points

To describe the clinical management, molecular diagnostic strategy, and treatment response of metastatic melanoma with right atrial involvement.
Evaluated a 42-year-old woman presenting with lumbar melanoma and right atrial metastasis.
Performed pyrosequencing on subcutaneous metastatic tissue to detect the BRAF V600E mutation after primary tumor DNA testing was nondiagnostic.
Administered sequential systemic immunotherapies and targeted BRAF/MEK inhibitors (dabrafenib and trametinib) guided by serial echocardiography and electrocardiography.
Targeted BRAF/MEK inhibitor therapy achieved complete resolution of the right atrial metastasis on transthoracic echocardiography before later disease recurrence.
Electrocardiography detected asymptomatic abnormalities including sinus tachycardia, low QRS voltage, and nonspecific ST-T wave changes.
Overall survival reached approximately 3.5 years following the diagnosis of cardiac metastasis.

Study Design

Type

Case Report (n=1)

Multicenter

Structured PICO

Population

A 42-year-old woman with malignant melanoma and right atrial metastasis who was treated with targeted therapy and survived for approximately 3.5 years after cardiac metastasis diagnosis.

Intervention

Multiple lines of systemic therapy, including pembrolizumab, ipilimumab, and BRAF/MEK inhibitors (dabrafenib and trametinib), with serial echocardiographic monitoring.

Outcome

Regression of right atrial metastasis on serial transthoracic echocardiographysurrogate

BRAF/MEK inhibitor therapy can achieve complete resolution of cardiac metastases from melanoma, highlighting the importance of molecular testing and multimodal imaging surveillance.

Limitations

Single case report
Recurrence of the cardiac lesion upon disease progression highlights the limitations of durable tumor control
Initial BRAF testing of archival tissue was nondiagnostic due to DNA degradation

Cite This Study

synapsesocial.com/papers/6a953aec6af7ed2fcaea0c63 https://doi.org/10.5603/ocp.112654

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark